Scaling up GMP-grade dopaminergic cells for Parkinson's disease
- PMID: 38181750
- DOI: 10.1016/j.stem.2023.12.005
Scaling up GMP-grade dopaminergic cells for Parkinson's disease
Abstract
Stem cell therapy for Parkinson's disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.F. has served on advisory boards for Peptron, Voyager Therapeutics, Handl therapeutics, Gain therapeutics, Living Cell Technologies, Abbvie, Bluerock, Bayer, Novo Nordisk, and Bial.
Comment on
-
Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease.Cell Stem Cell. 2024 Jan 4;31(1):25-38.e8. doi: 10.1016/j.stem.2023.11.009. Epub 2023 Dec 11. Cell Stem Cell. 2024. PMID: 38086390
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
